Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behçet’s disease

Sirs.

Behçet’s disease (BD) is a multi-systemic inflammatory disorder characterised by recurrent oral aphthosis, genital ulcers, cutaneous lesions and relapsing uveitis. Other clinical manifestations may derive from gastrointestinal, central nervous system, and vascular involvement (1). Mucocutaneous lesions may be the earliest and the most frequent manifestations of BD, thus anticipating by many years other symptoms (2). A strong Th1 immune response, with over secretion of proinflammatory cytokines such as interleukin (IL)-12 and interferon-γ, occurs in active Behçet’s disease (3). Moreover, an increase of Th17 lymphocytes in peripheral blood as well as increased serum levels of IL-17A have been observed (4). On this basis, the emergence of biological therapy targeting the IL-23/IL-17 axis might represent a viable treatment option in BD patients refractory to conventional treatments.

In this regard, we report herein a patient with BD showing mucosal and skin lesions successfully treated with ustekinumab, a monoclonal antibody targeting the p40 subunit IL-12/23.

A 16-year-old woman was referred to our Unit for a 3-year history of bilateral aphthosis and pustular skin lesions involving the chest and the upper and lower limbs. Mucosal and skin lesions were unresponsive to topical corticosteroids. She also complained of recurrent fever episodes. Upon admission, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were 70 mm/h (n.v <25) and 14.5 mg/dL (n.v <0.5) respectively. A full diagnostic work-up, including autoimmunity and screening for different infectious diseases, was negative. Considering that her medical history was relevant for recurrent fever episodes, the patient was also tested for mutations in the MEVY, TNFRSF1A, NRPL3, PSTPIP1 and MVK genes responsible for the most common hereditary periodic fever syndromes. No mutations were found. The HLA-B51 allele was positive. The patient fulfilled the International Study Group Criteria and was diagnosed with BD (5).

She had been successfully treated with high-dose of oral prednisone (1 mg/kg/day), but each attempt to taper corticosteroid dosage was followed by a disease relapse. Over the past years, colchicine (2 mg/day), methotrexate (up to 15 mg/week), cyclosporine (up to 5 mg/kg/day), and azathioprine (3–4 mg/kg/day) had failed to induce an adequate clinical remission. The tumour necrosis factor-inhibitors adalimumab (40 mg biweekly) and etanercept (50 mg weekly), had been also subcutaneously administered in an initial satisfying disease control, but both agents were withdrawn after a few months of treatment due to a rapid loss of efficacy over time. Therefore, the IL-1 receptor antagonist anakinra (100 mg/day) was then started, without inducing any amelioration of clinical manifestations. Anakinra was then interrupted and the patient was prescribed with ustekinumab at the induction dose of 45 mg at week 0 and 4, and then every 12 weeks, as recommended for refractory BD. A few weeks after the first injection of ustekinumab, the patient experienced the complete resolution of mucosal aphthous ulcers and of skin lesions. Acute phase reactants rapidly dropped to normal levels. Prednisone was gradually tapered to 5 mg/day. At 9-month follow-up, the patient was symptom-free and no adverse events were observed.

The decision to treat skin and mucosal lesions in BD is usually based on the perceived severity by the doctor and the patient and their management is usually driven by.codominant clinical involvements (6). In this regard, our patient showed refractory bilateral aphthosis and pustular skin lesions, which severely affected her quality of life. The evidence-based European League Against Rheumatism (EULAR) recommendations for BD management suggest that topical measures such as local corticosteroids should be the first line of therapy. A few weeks after the first injection of ustekinumab, the patient was symptom-free and no adverse events were observed.

In conclusion, ustekinumab rapidly determined the complete resolution of mucosal and skin lesions in our patient and also induced a rapid and stable normalisation of acute phase reactants. The treatment was well tolerated and no adverse events occurred. However, establishing ustekinumab long-term safety and effectiveness in BD still remains a challenge and further ad hoc studies on larger cohorts of patients are needed.

1. Department of Emergency and Organ Transplantation, Rheumatology Unit, University of Bari, Italy.
2. Department of Ophthalmology, Humanitas Research Centre, Milan, Italy.
3. Research Centre of Systemic Autoinflammatory Diseases and Behçet’s Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.

Please address correspondence to: Luca Cantarini, MD, PhD, Rheumatology Unit, Policlinico “Le Scotte”, University of Siena, Viale Bracci 1, 53100 Siena, Italy. E-mail: cantarini@luca@hotmail.com

© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2017.

Competing interests: none declared.

References
Letters to the Editors